For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 6,214,619 | |||
| Research and development | 9,771,940 | |||
| Total operating expenses | 15,986,559 | |||
| Loss from operations | -15,986,559 | |||
| Other expense | 2,560 | |||
| Interest income | 153,785 | |||
| Interest expense | 15,230 | |||
| Total other income (expense) | 135,995 | |||
| Net loss | -15,850,564 | |||
| Basic EPS | -35.75 | |||
| Diluted EPS | -35.75 | |||
| Basic Average Shares | 443,369 | |||
| Diluted Average Shares | 443,369 | |||
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)